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Guangming Wu1 and Hans R Schöler1,2*Abstract
Oct4 is a key component of the pluripotency regulatory network, and its reciprocal interaction with Cdx2 has been
shown to be a determinant of either the self-renewal of embryonic stem cells (ESCs) or their differentiation into
trophoblast. Oct4 of maternal origin is postulated to play critical role in defining totipotency and inducing
pluripotency during embryonic development. However, the genetic elimination of maternal Oct4 using a Cre-lox
approach in mouse revealed that the establishment of totipotency in maternal Oct4–depleted embryos was not
affected, and that these embryos could complete full-term development without any obvious defect. These results
indicate that Oct4 is not essential for the initiation of pluripotency, in contrast to its critical role in maintaining
pluripotency. This conclusion is further supported by the formation of Oct4-GFP– and Nanog- expressing inner cell
masses (ICMs) in embryos with complete inactivation of both maternal and zygotic Oct4 expression and the
reprogramming of fibroblasts into fully pluripotent cells by Oct4-deficient oocytes.
Keywords: Oct4, Oct4B, Totipotency, Pluripotency, Embryo, DevelopmentIntroduction
Life is like a journey of torch relay. From generation to
generation, our bodies vanish at the end of our lives, but
the germ cells are passed on to the next generation, en-
suring the continuity and prosperity of our species. In
comparison with the somatic cells, these germ cells pos-
sess many unique properties, of which the expression of
Oct4 is the most important as it is required for the sur-
vival of primordial germ cells (PGCs) [1,2]. Oct4 is also
expressed specifically in the inner cell mass (ICM) and
embryonic stem cells (ESCs), the cells derived from the
ICM [3]. Interestingly, Oct4 is expressed in mouse oo-
cytes as a maternal transcript and protein [1,4-6]. As is
typical for most maternal mRNAs, levels of Oct4 mRNA
drop dramatically after fertilization [6]. Zygotic Oct4 ex-
pression is activated prior to the 8-cell stage, with a sig-
nificant increase in both mRNA and protein levels [4,6].
Oct4 expression is abundant and uniform in all cells of
the embryo throughout the morula stage. However, as
the outer cells of the embryo differentiate into the
trophectoderm (TE), Oct4 expression becomes downreg-
ulated and restricted to cells of the ICM in the blastocyst* Correspondence: office@mpi-muenster.mpg.de
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article, unless otherwise stated.[5,7,8]. When cells of the primitive endoderm differenti-
ate and migrate away from the ectoderm, their Oct4
protein levels transiently increase [4]. Oct4 expression
then becomes downregulated in the primitive endoderm
and maintained in the epiblast, concurrently with em-
bryo implantation and gastrulation. Oct4 expression fi-
nally becomes restricted to PGCs [9], which are first
specified in the extraembryonic mesoderm at the base of
the allantoic bud during gastrulation [9]. PGCs give rise
to gametes, which can be fertilized to develop into a
new fully functional organism of the next generation
and complete one cycle of life (Figure 1).
Oct4, encoded by the gene Pou5f1, is a homeodomain
transcription factor of the POU (Pit-Oct-Unc) family. The
POU family of transcription factors can activate the ex-
pression of their target genes through binding to an octa-
meric sequence motif of an ATGCAAAT consensus
sequence. Oct4 protein consists of 3 domains: N-terminal
domain, POU domain, and a C-terminal domain. The
POU domain consists of two structurally independent
subdomains: a 75 amino acid amino-terminal POU-
specific (POUS) region and a 60 amino-acid carboxyl-
terminal homeodomain (POUHD). Both domains make
specific contact with DNA through a helix-turn-helix
structure and are connected by a linker of 17 amino acids.
Regions outside of the POU domain are not critical for
DNA binding and exhibit little sequence conservation.tral Ltd. This is an Open Access article distributed under the terms of the
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Figure 1 Oct4 expression during the mouse life cycle. Cells and
tissues expressing Oct4 are marked in green. Oct4 is expressed in
mouse oocytes as a maternal transcript and protein. Zygotic Oct4
expression is activated prior to the 8-cell stage and is abundant and
uniform in all cells of the embryo throughout the morula stage.
However, as the outer cells of the embryo differentiate into the TE,
Oct4 expression is restricted to cells of the ICM in the blastocyst.
After implantation, Oct4 expression is maintained in the epiblast.
Finally, Oct4 expression becomes restricted to primordial germ cells
(PGCs), which are first specified in the extraembryonic mesoderm at
the base of the allantoic bud during gastrulation. PGCs give rise to
gametes, which following fertilization will develop into a new
organism of next generation. Oct4 expression is based on data
previously reported by several studies [6,7,9-11].
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acidic residues, while the C-terminal domain (C-domain)
is rich in Proline, Serine, and Threonine residues. Both
the N-domain and the C-domain play an important role
in transactivation, but the activity of the C-domain is cell
type specific and is regulated through phosphorylation,
whereas that of the N-domain is not. The Oct4 POU-
domain functions differently by serving as an interaction
site for binding by cell type–specific regulatory factors
[12,13]. Oct4 has been deemed to be a critical regulator of
cellular pluripotency, as shown by a zygotic Oct4-knock-
out study [14]. Loss of pluripotency in embryos, observed
at the onset of somitogenesis, is coincident with reduction
of Oct4 and Nanog expression, and can be rescued by ec-
topic Oct4 expression [15]. Oct4 can activate its own ex-
pression with its transcription factor partner Sox2 through
a positive autoregulatory loop in ESCs [16]. Studies on
Oct4 interaction protein network have revealed that theOct4 interactome includes many transcription factors and
chromatin-modifying complexes with documented roles in
self-renewal and pluripotency, and that acute depletion of
Oct4 reduces the binding of Tcfcp2l1, Dax1, and Esrrb to
target genes [17-19]. Depletion of Oct4 by siRNA leads to
reduced binding of two key components of the bone mor-
phogenetic protein (BMP) and leukemia inhibitory factor
(LIF) signaling pathways, Smad1 and STAT3, to their re-
spective targets. This result indicates that Oct4 plays a piv-
otal role in stabilizing the nucleoprotein complex and
establishes a hierarchy of regulatory interactions between
Oct4, STAT3, and Smad1 [20]. The core components of
the pluripotency circuitry are formed by Oct4, Nanog, and
Sox2, and Nanog expression is directly regulated by Oct4
and Sox2 [21], Sox2 is actually dispensable for the activa-
tion of Oct-Sox enhancers, and the forced expression of
Oct4 could rescue Sox2-null ESCs [22]. Hence, Oct4 is con-
sidered to be the genetic "master switch" in the establish-
ment of totipotency-pluripotency during the life cycle of
mammals [23], and it is presumed to be the most upstream
gene in the molecular circuitry of pluripotency [24].
Maternal Oct4 expression is not critical for developmental
competence of the oocyte
All biological processes occurring during the first cell
cycle of the embryo rely on maternal factors, which have
accumulated during the long growth phase of the germi-
nal vesicle (GV) oocyte [25], because there is nearly no
mRNA synthesis between the end of the mouse oocyte
growth phase and the first zygotic cleavage [26]. But
during the second cell cycle, there is a burst of transcrip-
tion—what is known as zygotic genome activation
(ZGA) [27]. Mature metaphase II (MII) oocytes have the
capacity to reprogram somatic cells into cells of a toti-
potent state via nuclear transfer (NT) [28,29]. Therefore,
activation of zygotic transcripts mediated by maternal
regulatory factors provides the first step in the establish-
ment of totipotency/pluripotency. Oct4 is one of the 27
proven maternal-effect genes and is regarded to be func-
tionally important for zygotic genome activation [30].
Maternal Oct4 is therefore widely accepted to play a role
in igniting the establishment of totipotency and induc-
tion of pluripotency.
According to the chromatin organization, growing
mouse oocytes could be classified into 2 types: SN (sur-
rounded nucleolus) oocytes, with a ring of chromatin
surrounding the nucleolus, and NSN (not surrounded
nucleolus) oocytes, with chromatin dispersed throughout
the nucleus, i.e., chromatin not surrounding the nucle-
olus. When they mature into metaphase II (MII) oocytes
and are fertilized in vitro, only MIISN oocytes (MII oo-
cytes derived from SN oocytes) are developmentally
competent to develop beyond the 2-cell stage, while
MIINSN oocytes (MII oocytes derived from NSN oocytes)
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the transcriptional profiles of these two types of mouse
MII oocytes, Zuccotti et al. found that Oct4 was absent
in MIINSN oocytes, accounting for the downregulation of
Stella, a maternal-effect factor required for the oocyte-
to-embryo transition, and the upregulation of 18 Oct4-
regulated genes implicated in the activation of adverse
biochemical pathways such as oxidative phosphorylation,
mitochondrial dysfunction, and apoptosis. Those authors
concluded that the downregulation of Oct4 leads to the
developmental arrest of MIINSN oocytes and that mater-
nal Oct4 emerges as a key regulator of the molecular
events that govern the establishment of the developmen-
tal competence of mouse oocytes [32]. Moreover, an-
other study claimed that Oct4 is a critical regulator of
the maternal-embryonic transition at the 2-cell stage, as
embryos invasively injected with Oct4-antisense mor-
pholino oligonucleotides were found to arrest in various
developmental stages prior to the blastocyst stage [33].
A later report from the same group using the same ap-
proach also showed developmental arrest between the 2-
to 8-cell stages in morpholino-mediated Oct4, Nanog, or
Sall4 knockdown, but developmental arrest remained
obvious after co-injection of Oct4, Nanog, or Sall4
mRNA [34]. Although such a phenotype contradicts to
genetic knockout studies [14,35,36], which indicated that
homozygous null embryos could develop at least up to
the blastocyst stage, the authors ignored the presence of
maternal Oct4 protein and assumed that the apparent
discrepancy was due to the presence of functional ma-
ternal transcript [34]. However, recently, numerous stud-
ies found that after genetic removal of maternal Oct4 in
oocytes by crossing Oct4flox/flox/ZP3Cre/+female mice with
wild-type male mice, these Oct4flox/flox/ZP3Cre/+female
mice were found to be fully fertile [37-39]. All offspring
had deletion of the maternal Oct4 allele as confirmed by
polymerase chain reaction (PCR) genotyping, clearly
demonstrating that maternal Oct4 is not critical for the
establishment of totipotency-pluripotency [37]. The data
in the study also showed the efficient deletion of the ma-
ternal Oct4 allele by genotyping of individual oocytes,
the depletion of Oct4 mRNA by real-time reverse tran-
scriptase PCR (RT-PCR), and the depletion of Oct4 pro-
tein by Western blot [37].
Oct4-null oocytes can reprogram somatic cells to a
pluripotent state
Enucleated oocytes can also reprogram the nuclei of ter-
minally differentiated somatic cells to a totipotent em-
bryonic state after nuclear transplantation [28,29]. The
nuclei can be reprogrammed by the recipient oocytes
to express the pluripotent gene Oct4 at a very high effi-
ciency (88.7%) in just 2–3 days [40] and to give rise to
pluripotent cells at an efficiency of up to 20% [41]. Thiscompares favorably with the exciting 4-factor (Oct4, Sox2,
Klf4, and c-Myc) technique of generating induced pluripo-
tent stem cells (iPSCs) by Yamanaka and colleagues, which
showed activation of internal Oct4 expression after more
than 2 weeks, with an efficiency of 0.01–0.1% [42]. A re-
cent study revealed that Oct4 alone could reprogram
neural stem cells into pluripotent iPSCs [43]. Could ma-
ternal Oct4 in oocytes be essential in the reprogramming
of somatic cells to pluripotent status? The answer is no.
By conducting NT experiments using maternal Oct4-null
oocytes from Oct4flox/flox/ZP3Cre/+female mice, it was
found that all cloned embryos expressed pluripotency
genes (Oct4 and Nanog) in the ICM and the TE marker
gene Cdx2 in the TE by both immunocytochemistry and
real-time RT-PCR [37]. Furthermore, ESC lines derived
from cloned embryos using Oct4-knockout oocytes dem-
onstrated full pluripotency by generating completely ESC-
derived mice through the tetraploid complementation test,
the most stringent test for pluripotency [37]. Clearly, the
reprogramming engine in oocytes could work effectively
to reprogram somatic cells into cells of a pluripotent state
without the presence of maternal Oct4.
Reciprocal interaction between Oct4 and Cdx2 is not the
initial cause sparking ICM/TE lineage separation
Previous studies have suggested that lineage commit-
ment is controlled by the expression level of Oct4
[14,44]. Repression of Oct4 expression induced the
differentiation of ESCs into TE cells, and a less than
two-fold increase in Oct4 expression caused the differen-
tiation of ESCs into cells of primitive endoderm and
mesoderm [44]. In the absence of Oct4, embryos could
not form an ICM—i.e., the inner cells of morula-stage
embryos rather were driven into trophoblast differenti-
ation [14]. Therefore, these results indicated that Oct4
plays a critical role in sustaining stem cell self-renewal
and that up- or downregulation of Oct4 expression in-
duces divergent developmental programs, suggesting
that Oct4 is the master regulator of pluripotency and
that it may also control lineage commitment during
early embryonic development [14]. This hypothesis was
supported by reports showing that Oct4 and Cdx2 could
form a complex that reciprocally repressed their target
genes and such an interaction determined the ICM/TE
lineage separation in early embryos [45], while the
interaction between Oct4 and the histone H3–specific
methyltransferase ESET restricted the extraembryonic
trophoblast lineage potential of pluripotent cells [46].
However, the expression of Cdx2 in ESCs was found
to be rapidly initiated by Ras activation (i.e., within
24 hours) without previous or simultaneous downregula-
tion of Oct4 expression [47], while ESCs with reduced
Oct4 expression showed robust pluripotency and
expressed naïve pluripotency genes, but were deficient
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requisites [48,49]. On the other hand, Cdx2 deficiency
did not interrupt TE-ICM lineage separation [50-52],
and zygotic Oct4 expression was shown not to be re-
quired for the initial repression of the TE genes Cdx2
and Gata3 in the ICM, indicating that other mecha-
nisms are responsible for restricting the expression of
these genes to the TE [53]. Finally, with a conditional
knockout system, it was demonstrated that, similar to
the reported zygotic Oct4 knockout observation [14,53],
the genetic removal of both maternal and zygotic Oct4
did not prevent ICM-TE lineage separation [37-39], ar-
guing against the notion that maternal Oct4 could par-
tially compensate for the loss of zygotic Oct4 during cell
fate specification in the blastocyst [33]. Therefore, the
first lineage separation of the ICM-TE is not determined
by the reciprocal interaction between Oct4 and Cdx2.
More importantly, these studies indicated that maternal
Oct4 is not at the root of pluripotency as a determinant
of pluripotent cell lineage initiation, contrary to previous
assumptions and views [23,24].
How Oct4 is activated in the embryo remains an open
question
Oct4 is at the top of the pluripotency regulatory hierarchy
in pluripotent cells [20,21]. It forms a positive feedback
loop [16] and is essential to maintaining pluripotency [14],
but is not required for initiating totipotency/pluripotency
in embryos [37-39]. Therefore, understanding how early
embryos activate Oct4 expression is key in clarifying the
oocyte reprogramming mechanism.
The upstream region of the transcriptional initiation
site of the Oct4 gene contains three regulatory elements
for gene transcription: the distal enhancer (DE), prox-
imal enhancer (PE), and TATA-less proximal promoter
(PP) [9] as illustrated in Figure 2. The two enhancers ex-
hibit a differential activation pattern according to the de-
velopmental stage of the mouse embryo. The DE drives
Oct4 expression in the ICM, ESCs, and PGCs, while the
PE activates Oct4 expression in epiblast cells. Each en-
hancer contains multiple potential binding sites for tran-
scription factors that can either activate or repress Oct4
expression. In addition, the methylation of these regions
represses Oct4 expression in differentiated cells. Several
positive and negative regulators bind to the Oct4 gene to
regulate its expression. Of these, members of the orphan
nuclear receptor superfamily, which can bind to Sp1
sites [54] and hormone response elements (HREs) in the
PE and PP, are known to influence Oct4 expression.
Positive regulators of Oct4 expression include Nr5a2
[55], SF1 (Steroidogenic Factor-1), and RXR-β (Retinoid
X Receptor-β, also known as Nr2b2) [56,57]. Negative
regulators include GCNF (Germ Cell Nuclear Factor)
(also known as Nr6a1) [58], and COUF-TFI/II (ChickenOvalbumin Upstream promoter-Transcription Factors-
I/II), encoded by Nr2f1 and Nr2f2, respectively [59,60].
The transcription factor TR2 can bind to the HRE of the
Oct4 gene to either activate or repress Oct4 expression
in P19 embryonal carcinoma (EC) stem cells and regu-
late the proliferation of the culture, based on whether
there is SUMOylation on the Lys-238 of TR2 [61].
Recent studies have found that certain maternal fac-
tors are involved in the regulation of Oct4 expression,
providing clues on the mechanism underlying the initi-
ation of totipotency/pluripotency. Cancer-associated fac-
tor Tpt1 has been reported to activate the transcription
of Oct4 and Nanog in transplanted somatic nuclei in the
Xenopus oocyte [63], but another study failed to repli-
cate this finding upon knockdown of Tpt1 by Small
interfering RNA (siRNA) in the mouse embryos [37].
Components of the ATP-dependent BAF chromatin-
remodeling complex have been shown to significantly
increase reprogramming efficiency when used together
with the Yamanaka’s 4 factors [64]. Promyelocytic
leukemia (Pml) protein was found to be required for
Oct4 gene expression and the maintenance of its open
chromatin conformation in stem cells. In proliferating
stem cells, Pml-nuclear body, along with the transcrip-
tion factors TR2, SF1 and Sp1, and the Brg1-dependent
chromatin remodeling complex (BRGC), associates with
the Oct4 promoter to maintain a nucleosome-free region
for gene activity [65]. Studies in search for master genes
in the oocyte have revealed a novel oocyte-specific
eukaryotic translation initiation factor 4E (Eif4eloo) [66]
and a large number of oocyte-specific genes with yet un-
known functions, such as those belonging to the homeo-
domain transcription factor Obox family [67]. The
maternal transcription factor Sall4 binds to the Oct4 DE,
and it is regarded to be a transcriptional activator of
Oct4 expression based on evidence that reduction in
Sall4 mRNA level in blastocysts at merely 50% knock-
down efficiency by Sall4 siRNA injection into zygotes
led to a 70% reduction in Oct4 expression [68]. Single-
cell expression analyses during in vitro cellular repro-
gramming have confirmed that Sall4 is indeed an
upstream activator of Oct4 expression [69]. However, the
efficient knockdown of Sall4 by injecting Sall4 siRNA
into maternal Oct4-deficient zygotes—to avoid any
possible effect of maternal Oct4 as a positive autoregula-
tor—did not lead to any changes in Oct4 expression at
the blastocyst stage, arguing against such a role for Sall4
as an upstream activator of Oct4 expression in vivo [37].
Nr5a2 was found to maintain Oct4 expression at the
epiblast stage of embryonic development, by binding to
the PE and PP regions of Oct4, but to play no evident
role in ESC self-renewal [55]. However, Nr5a2 can in-
duce epiblast stem cells into ground state pluripotency,
a basal proliferative state that is free of epigenetic
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Figure 2 Genomic structure and transcriptional regulation of the mouse Oct4 gene. The diagram represents ~24 kb of the genomic region
surrounding the Oct4 gene [62]. The gene has five exons, depicted as blue boxes. The identified upstream regulatory regions include the
promoter, proximal enhancer, and distal enhancer. The sizes of the regulatory elements are stretched to enhance clarity. The transcription factors
bind to these regions, and are shown above within colored boxes; they either activate (green box) or repress (red box) transcription.
HRE = hormone responsive element; Sp1 = GC-rich site recognized by the Sp1/Sp3 family of transcription factors. CR1, CR2, CR3, and CR4 are
conserved regions (CRs) at the 5’ upstream region of the Oct4 gene.
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of somatic cells into pluripotent cells [71]. Activation of
Zscan4 expression occurs during ZGA, with the gene
being expressed in ESCs, whereas reduction in Zscan4
transcript levels by siRNAs delays the progression from
the 2-cell to the 4-cell stage, leading to blastocysts that
fail to implant or proliferate in blastocyst outgrowth cul-
ture [72]. Zscan4 is essential for induction of iPSCs and
its ectopic expression can activate early embryonic genes
and improve the efficiency of iPSC generation [73].
However, knockdown of Zscan4 in preimplantation em-
bryos by siRNA against all 6 isoforms of Zscan4 (a-f )
had no impact on Oct4 expression [37]. A component of
an active DNA demethylase, activation-induced cytidine
deaminase (AID), was also shown to be required for re-
programming [74]. A genome-scale RNA interference
(RNAi) screen in ESCs identified components of the
Paf1 complex with strong effects on Oct4 expression,
and showed that Paf1C overexpression blocks the differ-
entiation of ESCs and that Paf1C knockdown causes ex-
pression changes in ESCs that are similar to those
observed with Oct4 or Nanog depletion [75].
Oct4B expression in oocytes and embryos
After the finding that truncated isoforms of OCT4 are
transcribed from the POU5F1 gene in human [76] and
mouse [77], the originally described OCT4 is designated
as OCT4A and the newly found truncated isoforms are
variants of an OCT4 version named OCT4B [78].
OCT4B mRNAs encode proteins that have identical
POU DNA-binding domains and C-domains but differ
in their N-domains (Figure 3). Continued expression of
Oct4B after the original Oct4 promoter was removed in-
dicates that Oct4B transcription is regulated by an alter-
native promoter in the first intron [37], as presumed byan earlier study [79]. Other isoforms of Oct4B could be
produced by alternative splicing or alternative transla-
tion initiation [80,81]. ESC-based complementation as-
says using ZHBTc4 ESCs, which has endogenous Oct4
inactivated by gene targeting and harbors a tetracycline-
repressible Oct4 transgene to support ESC self-renewal
[44], showed that OCT4B cannot rescue the self-renewal
ability of ZHBTc4 ESCs in the presence of doxycycline,
unlike OCT4A. Electrophonetic mobility shift assay
showed that OCT4B does not bind to a probe carrying
the OCT4 consensus binding sequence due to the re-
pressive effect of the OCT4B N-domain. Furthermore,
overexpression of OCT4B does not activate transcription
from OCT4-dependent promoters [78]. However, Oct4B
is involved in stress response [82] and acts as an antia-
poptotic factor in cancer cells [83].
On the other hand, Oct4 expression in the adult has
been reported in hematopoietic and mesenchymal stem
cells [84-95], as well as progenitor cells from various
somatic tissues including pancreatic islets [96], kidney
[97,98], peripheral blood [89,99,100], endometrium of
the uterus [101,102], thyroid [103], lung [104], brain
[105,106], liver [107], and skin [108-111]. The wide ex-
pression of Oct4 in normal tissues suggests that Oct4
may not only be crucial for the maintenance of pluripo-
tency in embryonic cells, but also play an important role
in the self-renewal of somatic stem cells and in mainten-
ance of tissue homeostasis. As these studies did not dis-
tinguish the Oct4 isoforms, it is likely they actually
detected Oct4B. A later study that conditionally deleted
Oct4 from somatic cells in vivo found that Oct4 is dis-
pensable for both the self-renewal and maintenance of
somatic stem cells in the adult mammal [112]. Oct4
gene ablation in the intestinal epithelium, bone marrow
(hematopoietic and mesenchymal lineages), hair follicle,
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Figure 3 Schematic representation of the protein domains of the mouse Oct4 isoforms and the corresponding exons. Exon1B of Oct4B
is in the intron 1–2 region of the Oct4 gene. Modified from Guo et al. 2012 [81].
Wu and Schöler Cell Regeneration 2014, 3:7 Page 6 of 10
http://www.cellregenerationjournal.com/content/3/1/7brain, and liver revealed no abnormalities in homeostasis
or regenerative capacity [112]. Like many other publications
claiming Oct4 expression in somatic stem cells, this study
also noted low level of expression but that was regarded as
false detection of Oct4 due to the noise of the detection
methods, expression of pseudogenes, and expression of
other POU-domain family members [112]. These conclu-
sions are now in question. In our lab, the same Oct4floxed
mice were used, in which two LoxP motifs had been
inserted that span the proximal promoter and the Oct4A-
unique first exon [2]. As the other 4 exons shared by Oct4B
were not mutated, it is still possible that Oct4B can still be
transcribed using an alternative promoter. After efficiently
removing the floxed sequence of Oct4 in oocytes by cross-
ing the Oct4flox/flox mice with ZP3Cre transgenic mice, in-
deed, the expression of only Oct4B (not Oct4A) was
detected at low levels by RT-PCR in the mutated oocytesOogenesis 
( 2 weeks) 
Ovulation 
Oct4 re-expression at 2 dpp 
 
ZP3Cre-mediated deletion of Oct4 
at 5 dpp prevents accumulation 
of maternal Oct4 
Accumulation of maternal 
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Figure 4 Development of maternal Oct4–depleted embryos. Totipoten
absence of Oct4, and these embryos can maintain pluripotency and comp
paternal allele Oct4 gene at the late 4-cell stage. The lower panel shows th
Nanog-positive ICM and Cdx2-positive TE lineages are still established. How
lineage separation, and it fails to further develop at around the time of imp
genome activation.and preimplantation embryos, which was confirmed by se-
quencing. Another recent report used a different Oct4-
floxed mouse line to delete the entire Oct4 POU domain
and C-domain, yet the authors of that study also observed
full-term development of maternal Oct4–null embryos and
TE/ICM lineage separation, as well as Nanog activation in
maternal and zygotic Oct4–null embryos [39]. Taken to-
gether, these studies confirmed that (1) maternal Oct4 is in-
deed not essential for the establishment of totipotency. (2)
The low levels of Oct4B expression could not rescue
Oct4A-null embryos to maintain pluripotency in vivo
[37,38]. The precise function of Oct4B in embryos and
somatic stem cells remains to be clarified.
Conclusion
As summarized in Figure 4, new pieces of evidence
clearly indicate that Oct4 is not the master regulatorPluripotency 
tic Oct4  
tion First lineage  
specification 













cy in maternal Oct4–depleted embryos can be established in the
lete full-term development, supported by the zygotic activation of the
at in the absence of both maternal and zygotic Oct4 expression, the
ever, this ICM cannot maintain pluripotency and complete the second
lantation. dpc: days post coitum; dpp: days post partum; ZGA: zygotic
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oocytes, and that maternal and zygotic Oct4–null blas-
tocysts maintain the ability to activate Nanog and Oct4-
GFP expression, indicating that unknown pathways
other than the Oct4-centered pluripotency-regulating
network are active in embryos and function upstream of
Oct4 in driving pluripotency. However, to date no fac-
tors have proven to be essential for Oct4 activation in
the preimplantation embryos. Further studies are re-
quired to elucidate how oocytes activate the pluripotent
genes Oct4 and Nanog on top of the Oct4/Sox2 autore-
gulatory loop in an effort to understand the establish-
ment of totipotency in zygotes and in transplanted
somatic cells.
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